gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Glioma-expressed antigen 2 (GLEA2): a protein that can elicit immune response in glioblastoma patients

Glioma-expressed antigen 2 (GLEA2): ein Protein, das eine Immunantwort in Glioblastom Patienten hervorrufen kann

Meeting Abstract

  • corresponding author A. Prowald - Neurochirurgische Klinik, Universität des Saarlandes, Homburg-Saar
  • R. Ketter - Neurochirurgische Klinik, Universität des Saarlandes, Homburg-Saar
  • C. Pallasch - Institut für Humangenetik, Universität des Saarlandes, Homburg-Saar
  • W. I. Steudel - Neurochirurgische Klinik, Universität des Saarlandes, Homburg-Saar
  • E. Meese - Institut für Humangenetik, Universität des Saarlandes, Homburg-Saar
  • U. Fischer - Institut für Humangenetik, Universität des Saarlandes, Homburg-Saar

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. DocP180

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2005/05dgnc0448.shtml

Veröffentlicht: 4. Mai 2005

© 2005 Prowald et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Glioblastoma multiforme is the most frequent and malignant brain tumor of astrocytic origin. The average survival time of less than 16 months underlines the need for improvements in diagnosis and therapy. The high intratumoral heterogeneity associated with a complex antigen pattern complicates the development of specific diagnostic markers. Tumor associated antigens (TAAs) offer themselves as markers and as tools to access altered cellular pathways in glioblastoma. With astrocytes as an essential part of the blood brain barrier, this barrier is impaired in glioblastoma allowing antigens to have contact with immune competent cells.

Methods

A consecutive series of blood samples were taken prior to surgery from 39 glioblastoma patients and for control group from 14 healthy persons. Serum was isolated from 10 ml blood samples by using standard protocol. The immune response was determined by the SEREX approach. In patients with immune response clinical data were compared with data from patients without immune response.

Results

We identified a novel antigen termed glioma- expressed antigen 2 (GLEA2) causing an immune response in glioma patients. We found the immune response in 17 out of 39 sera from glioblastoma patients (43%) using allogenic sera. Sera from healthy individuals showed an immune response only in few cases (14%). GLEA2 appears to be ubiquitously expressed in various normal tissues.

Conclusions

There are numerous glioma-associated antigens, which are characterized by a differential expression in glioma versus normal cells. However the majority of the glioma-associated antigens, have been found to be of minor diagnostic utility. Our primarily data indicate that GLEA2 is likely to be a potential future diagnostic marker in the treatment of gliomas.